[
    [
        {
            "time": "2023-11-01",
            "original_text": "贝达药业：新药项目MIL60达到主要研究终点 可用于治疗肺癌患者",
            "features": {
                "keywords": [
                    "贝达药业",
                    "新药",
                    "MIL60",
                    "临床试验",
                    "肺癌"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：新药项目MIL60达到主要研究终点 可用于治疗肺癌患者",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "贝达药业(300558.SZ)披露新药项目MIL60临床试验进展 III期研究达到主要研究终点",
            "features": {
                "keywords": [
                    "贝达药业",
                    "MIL60",
                    "III期",
                    "临床试验",
                    "研究终点"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)披露新药项目MIL60临床试验进展 III期研究达到主要研究终点",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "贝达药业：新药项目MIL60将开展申请注册及申报生产的相关工作",
            "features": {
                "keywords": [
                    "贝达药业",
                    "MIL60",
                    "注册",
                    "生产",
                    "申请"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：新药项目MIL60将开展申请注册及申报生产的相关工作",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "贝达药业：多名股东合计减持达到1%股份 减持股份数量较大",
            "features": {
                "keywords": [
                    "贝达药业",
                    "减持",
                    "股东",
                    "股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：多名股东合计减持达到1%股份 减持股份数量较大",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "贝达药业(300558.SZ)：3名股东已合计减持401万股 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "减持",
                    "股东",
                    "401万股"
                ],
                "sentiment_score": -0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：3名股东已合计减持401万股 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "药品临床试验申请被受理 贝达药业大涨5.64%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "临床试验",
                    "申请受理",
                    "大涨"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药品临床试验申请被受理 贝达药业大涨5.64%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "年底雷声渐多，43股连续两年亏损，其中15股已资不抵债 亏损",
            "features": {
                "keywords": [
                    "亏损",
                    "资不抵债",
                    "股票"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "年底雷声渐多，43股连续两年亏损，其中15股已资不抵债 亏损",
                "Correlation": 3,
                "Sentiment": 2,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]